Recommendation of the President – Kinpeygo (budesonide)
On 16 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 34/2026 regarding the inclusion of the medicinal product Kinpeygo (budesonide) in the reimbursement program: B.171. “Treatment of patients with primary IgA nephropathy (ICD-10: N02.8)”